Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
about
The Novel PKCθ from Benchtop to ClinicMechanisms of drug resistance in kinases.Diabetic macular edema: therapeutic options.Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads.Protein kinase Cβ2 inhibition reduces hyperglycemia-induced neural tube defects through suppression of a caspase 8-triggered apoptotic pathway.Novel drugs and their targets in the potential treatment of diabetic retinopathy.Protein kinase C isozymes as regulators of sensitivity to and self-administration of drugs of abuse-studies with genetically modified mice.RhoA/rock signaling mediates peroxynitrite-induced functional impairment of Rat coronary vesselsDiabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCβ2.Protein kinase C controls vesicular transport and secretion of apolipoprotein E from primary human macrophages.Hyperglycemia-induced protein kinase C β2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling.PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice.Emerging drugs for diabetic neuropathy.Oxidative stress in early diabetic nephropathy: fueling the fire.Diabetic neuropathy: cellular mechanisms as therapeutic targets.Diabetic macular edema: current and emerging therapies.Systems kinomics for characterizing host responses to high-consequence pathogens at the NIH/NIAID Integrated Research Facility-Frederick.Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.Multifunctional roles of PKCδ: Opportunities for targeted therapy in human diseaseReactive oxygen species: sources, consequences and targeted therapy in type 2 diabetes.PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1).Glycine Protects H9C2 Cardiomyocytes from High Glucose- and Hypoxia/Reoxygenation-Induced Injury via Inhibiting PKCβ2 Activation and Improving Mitochondrial Quality.Structural basis of conformational variance in phosphorylated and non-phosphorylated states of PKCβII.Protein Kinase C (PKC) Isozymes and Cancer
P2860
Q27024068-AB633F22-35B4-49A8-89A4-944516F6C816Q27692567-9E31E4EE-3ABF-4FDD-9462-145DDB505F32Q34185374-67AECD71-2788-40CC-83DC-3F64AA230744Q34553087-4CE1A0F9-4C8A-4E59-BF1A-98A128391226Q34673067-74AA7435-1E72-438C-9F7C-5E17F41290CDQ34688209-E25B84C9-7629-41A2-B896-51C86D93A214Q34761380-41680F37-64FE-4716-8B94-7C1316FDD57FQ36159672-0D43104F-2CFF-4EBF-A9E4-C5462584103DQ36312528-E9A0DA93-C67A-481D-A03D-B285C96EB4EBQ36620898-430E0E32-E399-488D-9725-F34F98CA1EA4Q37015027-F628B061-F975-405D-B667-9DE9BC852821Q37397476-33048123-BFE9-4C29-9683-BE65345307A7Q37783301-867752BB-7A4A-46E9-A848-E2F4BE12C7F1Q37820092-8CE5185D-F5A0-4461-88A0-E180CE4DBFC3Q37930962-BF6E608D-900C-4C34-8794-03084F2BBB34Q37985854-3AFC1ACD-A405-4F7F-9D05-49079CCE91F5Q38192567-FE09F64D-F5EA-44D1-998D-A90F2FF01FCDQ38798588-5A3FF51E-35C2-4AA6-8BAB-14666DCCAEBDQ38834586-12C73C20-3340-400B-AFC9-5E186AD4B6E1Q38880678-37B78D5F-8BB9-46BA-9F54-6B97DCCEB48BQ42125422-5E3FB13C-6512-4A16-BA0E-1E6584B67936Q54232641-8ACD2E26-2AF2-4024-845A-1C3DB14A2298Q55018528-094ABC6B-A3E9-4FA5-BE9D-FB9C63E9CB0BQ55072903-AB2C1D66-B005-46FF-8614-72ABD18F5E26Q59072618-D93929D8-D9D5-4893-9D59-6D92F2121C12
P2860
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
@en
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
@nl
type
label
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
@en
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
@nl
prefLabel
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
@en
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
@nl
P2860
P1476
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
@en
P2093
Matthew J Sheetz
Ronald P Danis
P2860
P304
P356
10.1517/14656560903401620
P407
P577
2009-12-01T00:00:00Z